A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP
复制标题
利妥昔单抗联合 rhTPO 与利妥昔单抗治疗皮质类固醇耐药或复发性 ITP 的多中心随机开放标签研究
DOI：
10.1182/blood-2014-06-581868
复制
发表时间：
2015-03-05
期刊：
影响因子：
20.3
通讯作者：
Hou, Ming
中科院分区：
文献类型：
--
作者：
Zhou, Hai;Xu, Miao;Hou, Ming
本研究旨在比较利妥昔单抗 (RTX) 加重组人血小板生成素 (rhTPO) 与单独使用 RTX 对皮质类固醇无反应或复发的免疫性血小板减少症 (ITP) 患者的疗效和安全性。招募的患者以 2:1 的比例随机分为 2 组：联合组（RTX + rhTPO，n = 77）和单药治疗组（RTX，n = 38）。联合治疗组的总体缓解率为 79.2%，而单药治疗组为 71.1% (P = .36)，联合治疗组的完全缓解 (CR) 率为 45.4%，而单药治疗组为 23.7% (P = .026)。与单药治疗组（28 天和 4-90 天）相比，联合治疗组的缓解时间（TTR；中位数和范围，7 天和 4-28 天）显着更短（P
This study aimed to compare the efficacy and safety of rituximab (RTX) plus recombinant human thrombopoietin (rhTPO) with RTX alone in patients with immune thrombocytopenia (ITP) who had failed to respond to corticosteroids or relapsed. Recruited patients were randomized at a ratio of 2: 1 into 2 groups: the combination group (RTX + rhTPO, n = 77) and the monotherapy group (RTX, n = 38). Overall response was achieved in 79.2% of patients in the combination group vs 71.1% in the monotherapy group (P = .36), and the complete response (CR) rate was 45.4% in the combination group compared with 23.7% in the monotherapy group (P = .026). The combination group had significantly shorter time to response (TTR; median and range, 7 and 4-28 days) compared with the monotherapy group (28 and 4-90 days) (P